My laboratory is actively engaged in basic, translational and clinical research focused in the field of women’s reproductive health. From the oncology perspective, my group molecularly interrogates gynecologic tumors to identify novel cell signaling pathways that contribute to malignant transformation, the pathology of the disease, recurrence and resistance to therapy. Once key factors or pathways are identified, we actively test novel anti-cancer drugs to determine their efficacy in tumor explant models. In addition to my role as a scientist, I am the Executive Director of the MGH Gyn Tissue Repository. The repository infrastructure is extensive and is designed to collect malignant and benign tissues along with clinically annotated information. To complement the banking efforts I have developed a Bio-Banking infrastructure. To this end we utilize a well-established in vivo experimental system in which primary tumors collected from endometrial and ovarian cancer patients at the time of initial surgery are grown in NOD/SCID mice. These explanted tumors and the primary tumors are genotyped and undergo cryopreservation using state of the art techniques. Once thawed, the tumors can be propagated in vivo through serial transplantation over several passages while retaining their original genotype and histophenotype. This allows for the generation of large cohorts of mice hosting matched xenograft tumors ready for use in multi-armed therapeutic experiments. Our work to date provides evidence to suggest the clinical course of the primary tumor mimics the behavior and responses we have seen in our explants further supporting the potential clinical utility of our xenograft model. This model is especially important for our proposed studies with whereby we are investigating the genetic and protein pathways contributing to the resistance to PI3K and HER signaling pathway inhibition using high throughput molecular analyses. It is believed the data generated from our investigations will directly inform the design of future combination trials in advanced gynecologic cancers.